Heart Failure Treatment in 2023: Is There a Place for Lipid Lowering Therapy?

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F23%3A00079465" target="_blank" >RIV/00159816:_____/23:00079465 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/23:00133673

Výsledek na webu

<a href="https://link.springer.com/article/10.1007/s11883-023-01166-3" target="_blank" >https://link.springer.com/article/10.1007/s11883-023-01166-3</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s11883-023-01166-3" target="_blank" >10.1007/s11883-023-01166-3</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Heart Failure Treatment in 2023: Is There a Place for Lipid Lowering Therapy?

Popis výsledku v původním jazyce

Purpose of ReviewAn evidence for lipid lowering therapy in heart failure is briefly summarized in this review.Recent FindingsHeart failure therapy is based on recent guidelines for diagnosis and treatment of acute and chronic heart failure. The question of the importance of hypolipidemic treatment in heart failure remains insufficiently answered. We still rely only on results of two randomized controlled trials that did not show significant benefit of statins on mortality in these patients. In contrast, some meta-analysis, prospective or retrospective cohorts, found some positive effects of this therapy. Recently, the role of inflammation and the possibility of its influence by hypolipidemics have been discussed. PCSK9 inhibitors, new lipid lowering drugs, are very effective in LDL-cholesterol lowering and atherosclerotic cardiovascular diseases prevention. The role of PCSK9 inhibitors in heart failure treatment is investigated.SummaryBased on current knowledge, hypolipidemics are not generally recommended in heart failure therapy, unless there is another indication for their use.

Název v anglickém jazyce

Heart Failure Treatment in 2023: Is There a Place for Lipid Lowering Therapy?

Popis výsledku anglicky

Purpose of ReviewAn evidence for lipid lowering therapy in heart failure is briefly summarized in this review.Recent FindingsHeart failure therapy is based on recent guidelines for diagnosis and treatment of acute and chronic heart failure. The question of the importance of hypolipidemic treatment in heart failure remains insufficiently answered. We still rely only on results of two randomized controlled trials that did not show significant benefit of statins on mortality in these patients. In contrast, some meta-analysis, prospective or retrospective cohorts, found some positive effects of this therapy. Recently, the role of inflammation and the possibility of its influence by hypolipidemics have been discussed. PCSK9 inhibitors, new lipid lowering drugs, are very effective in LDL-cholesterol lowering and atherosclerotic cardiovascular diseases prevention. The role of PCSK9 inhibitors in heart failure treatment is investigated.SummaryBased on current knowledge, hypolipidemics are not generally recommended in heart failure therapy, unless there is another indication for their use.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

<a href="/cs/project/LX22NPO5104" target="_blank" >LX22NPO5104: Národní institut pro výzkum metabolických a kardiovaskulárních onemocnění</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Current Atherosclerosis Reports

ISSN

1523-3804

e-ISSN

1534-6242

Svazek periodika

25

Číslo periodika v rámci svazku

12

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

8

Strana od-do

957-964

Kód UT WoS článku

001118155800003

EID výsledku v databázi Scopus

—